Plant ID: NPO20414
Plant Latin Name: Ocimum basilicum
Taxonomy Genus: Ocimum
Taxonomy Family: Lamiaceae
NCBI TaxonomyDB:
39350
Plant-of-the-World-Online:
n.a.
Antibacterial; Antidepressant; Antirheumatic; Antispasmodic; Appetizer; Aromatherapy; Aromatic; Carminative; Digestive; Galactogogue; Ophthalmic; Stomachic; Tonic
Brazil; Israel; Italy; Mexico; Lebanon; Philippines; Indonesia; India; Rwanda; China; Kenya; Switzerland; Jordan; Argentina; Tanzania; Nigeria; Thailand
TSHR; | |
MAPK1; | |
TP53; | |
MAPT; LMNA; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 9.320E-10 | 1.775E-05 | CYP1A2, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.024E-08 | 7.433E-05 | CYP1A2, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 8.226E-08 | 4.478E-04 | CYP1A2, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 4.502E-07 | 1.634E-03 | CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 6.563E-07 | 2.042E-03 | CYP1A2, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 9.002E-07 | 2.178E-03 | CYP1A2, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 9.886E-06 | 1.493E-02 | CYP1A2, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.097E-05 | 1.493E-02 | CYP1A2, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0020037; heme binding | 1.554E-05 | 1.879E-02 | CYP1A2, CYP2D6, CYP3A4 |
CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 3.274E-04 | 1.478E-01 | MAPK1, MAPT |
CC | GO:0043226; organelle | GO:0016604; nuclear body | 2.450E-03 | 3.580E-01 | LMNA, MAPT, TP53 |
CC | GO:0044464; cell part | GO:0030424; axon | 4.683E-03 | 4.552E-01 | MAPK1, MAPT |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 5.052E-03 | 4.681E-01 | CYP1A2, CYP2D6, CYP3A4 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 2.174E-06 | 1.508E-04 | CYP2D6, CYP1A2, CYP3A4 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 2.579E-06 | 1.508E-04 | CYP2D6, CYP1A2, CYP3A4 |
09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 1.832E-05 | 7.146E-04 | LMNA, MAPK1, TP53 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04010 | MAPK signaling pathway | 1.094E-04 | 1.904E-03 | MAPK1, MAPT, TP53 |
09160 Human Diseases | 09161 Cancers | hsa05216 | Thyroid cancer | 5.654E-05 | 1.323E-03 | MAPK1, TP53 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 5.654E-05 | 1.323E-03 | CYP1A2, CYP3A4 |
09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 2.133E-04 | 2.383E-03 | MAPK1, TP53 |
09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 1.838E-04 | 2.383E-03 | MAPK1, TP53 |
09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 1.139E-04 | 1.904E-03 | MAPK1, TP53 |
09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 2.876E-04 | 2.383E-03 | MAPK1, TP53 |
09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 2.616E-04 | 2.383E-03 | MAPK1, TP53 |
09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 2.965E-04 | 2.383E-03 | MAPK1, TP53 |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.289E-04 | 2.383E-03 | CYP1A2, CYP3A4 |
09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 3.431E-04 | 2.497E-03 | MAPK1, TP53 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 2.876E-04 | 2.383E-03 | CYP1A2, CYP3A4 |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 3.056E-04 | 2.383E-03 | MAPK1, TP53 |
09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 3.627E-04 | 2.497E-03 | MAPK1, TP53 |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 5.388E-04 | 3.318E-03 | MAPK1, TP53 |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 8.513E-04 | 4.966E-03 | CYP2D6, MAPK1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 9.443E-04 | 4.966E-03 | MAPK1, TP53 |
09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 9.763E-04 | 4.966E-03 | MAPK1, TP53 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 4.576E-04 | 2.974E-03 | CYP1A2, CYP3A4 |
09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 1.440E-03 | 6.739E-03 | MAPK1, TP53 |
09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 1.197E-03 | 5.836E-03 | MAPK1, TP53 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 9.763E-04 | 4.966E-03 | MAPK1, TP53 |
09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05010 | Alzheimer's disease | 1.900E-03 | 8.549E-03 | MAPK1, MAPT |
09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 1.999E-03 | 8.661E-03 | CYP1A2 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MAPK1; TP53; |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; |
C00-D49: Neoplasms | Cancer | C00-C96 | MAPK1; TP53; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT; |